Cargando…

TBX2 Expression predicts Tumor Recurrence and Adjuvant Chemotherapy Benefits in Gastric Cancer Patients following R0 Resection: a proposed approach for risk stratification

Aims: TBX2 is related to tumor progression and drug resistance. However, the roles of TBX2 in gastric cancer (GC) remain unclear. Our study aims at investigating the clinical roles of TBX2 in GC. Methods: The protein expression levels of TBX2 in fresh GC tissue (n=20) were investigated with Western...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Jun, Xu, Yu, Wang, Yao-hui, Huang, Xiao-yan, Wu, Yuan, Xie, Jian-wei, Wang, Jia-bin, Lin, Jian-xian, Li, Ping, Zheng, Chao-hui, Huang, Ai-min, Huang, Chang-ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097955/ https://www.ncbi.nlm.nih.gov/pubmed/32231721 http://dx.doi.org/10.7150/jca.34929

Ejemplares similares

Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer
por: Lu, Jun, et al.
Publicado: (2019)

Is Adjuvant Chemotherapy Beneficial to All Patients With pT3N0M0 Stage Gastric Cancer?
por: Huang, Jiao-Bao, et al.
Publicado: (2021)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)

Benefit of Adjuvant Traditional Herbal Medicine With Chemotherapy for Resectable Gastric Cancer
por: Lee, Yu Kyung, et al.
Publicado: (2018)

Adjuvant chemotherapy or no adjuvant chemotherapy? A prediction model for the risk stratification of recurrence or metastasis of nasopharyngeal carcinoma combining MRI radiomics with clinical factors
por: Wu, Qiaoyuan, et al.
Publicado: (2023)

Indications for adjuvant chemotherapy in patients with AJCC stage IIa T3N0M0 and T1N2M0 gastric cancer—an east and west multicenter study
por: Huang, Ze-Ning, et al.
Publicado: (2019)

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
por: Tang, Lirui, et al.
Publicado: (2022)

Rectal cancer patients with downstaging after neoadjuvant chemoradiotherapy and radical resection do not benefit from adjuvant chemotherapy
por: Zhang, Hang, et al.
Publicado: (2020)

Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection
por: Shi, Jinming, et al.
Publicado: (2022)

Efficacy and safety of adjuvant chemotherapy in T1N0M0 intrahepatic cholangiocarcinoma after radical resection
por: Li, Xiao-hui, et al.
Publicado: (2022)

Perioperative CRP: A novel inflammation‐based classification in gastric cancer for recurrence and chemotherapy benefit
por: Lu, Jun, et al.
Publicado: (2020)

Risk stratification system to predict recurrence of intrahepatic cholangiocarcinoma after hepatic resection
por: Jeong, Seogsong, et al.
Publicado: (2017)

The Survival Benefits of Surgical Resection and Adjuvant Therapy for Patients With Brainstem Glioma
por: Liu, Zhuoyi, et al.
Publicado: (2021)

High LARGE1 Expression May Predict Benefit from Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer
por: Liu, Yu, et al.
Publicado: (2021)

Adjuvant Chemotherapy in Node-Negative Advanced Gastric Cancer Patients
por: Su, Jian-wei, et al.
Publicado: (2022)

Preoperative Splenic Density for the Prediction of Survival and Adjuvant Chemotherapy Benefits in Gastric Cancer
por: Zhang, Wei-teng, et al.
Publicado: (2020)

Evaluation of dynamic recurrence risk for locally advanced gastric cancer in the clinical setting of adjuvant chemotherapy: a real-world study with IPTW-based conditional recurrence analysis
por: Wu, Dong, et al.
Publicado: (2023)

Early Recurrence of Pancreatic Cancer after Resection and During Adjuvant Chemotherapy
por: Fischer, Richard, et al.
Publicado: (2012)

Update of Adjuvant Chemotherapy for Resected Gastric Cancer
por: Oh, Sang Cheul
Publicado: (2012)

Development and External Validation of a Nomogram to Predict Recurrence-Free Survival After R0 Resection for Stage II/III Gastric Cancer: An International Multicenter Study
por: Lu, Jun, et al.
Publicado: (2020)

A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy
por: Qian, Jing, et al.
Publicado: (2016)

Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
por: Lin, Jian-Xian, et al.
Publicado: (2022)

Radiomics nomogram for prediction disease-free survival and adjuvant chemotherapy benefits in patients with resected stage I lung adenocarcinoma
por: Xie, Dong, et al.
Publicado: (2020)

Benefits from Adjuvant Chemotherapy in Patients with Resected Non-Small Cell Lung Cancer: Possibility of Stratification by Gene Amplification of ACTN4 According to Evaluation of Metastatic Ability
por: Tozuka, Takehiro, et al.
Publicado: (2022)

Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling
por: Xylinas, E, et al.
Publicado: (2012)

Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection
por: Kang, Wen-Zhe, et al.
Publicado: (2022)

Role of adjuvant chemotherapy on recurrence and survival in patients with resected ampulla of Vater carcinoma
por: Park, Se Jun, et al.
Publicado: (2023)

Elderly patients with stage II gastric cancer do not benefit from adjuvant chemotherapy
por: Guo, Jianping, et al.
Publicado: (2023)

Independent Risk Factors of Early Recurrence After Curative Resection for Perihilar Cholangiocarcinoma: Adjuvant Chemotherapy May Be Beneficial in Early Recurrence Subgroup
por: Zhao, Jian, et al.
Publicado: (2020)

A Novel Insight Into Fecal Occult Blood Test for the Management of Gastric Cancer: Complication, Survival, and Chemotherapy Benefit After R0 Resection
por: Lu, Jun, et al.
Publicado: (2021)

Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0
por: You, Kai-yun, et al.
Publicado: (2014)

Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer: a propensity-matched analysis
por: Quan, RenCui, et al.
Publicado: (2016)

Development and Validation of a Nomogram to Predict the Benefit of Adjuvant Radiotherapy for Patients with Resected Gastric Cancer
por: Yuan, Shu-Qiang, et al.
Publicado: (2017)

Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis
por: Wu, Chenghui, et al.
Publicado: (2023)

Adrenocortical Carcinoma in an Adult: Eight Months without Recurrence after Resection and Adjuvant Chemotherapy
por: Siosaki, Marcos Duarte, et al.
Publicado: (2014)

Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2019)

The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
por: Kim, Young Saing, et al.
Publicado: (2017)

An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer
por: Wang, Jia-Bin, et al.
Publicado: (2020)

The benefit of adjuvant radiotherapy on overall survival in resected stage I to II pancreatic cancer: A propensity-adjusted analysis
por: Lin, Zhuang-Bin, et al.
Publicado: (2020)

Clinicopathological features and impact of adjuvant chemotherapy on the long-term survival of patients with multiple gastric cancers: a propensity score matching analysis
por: Lin, Jian-Xian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ujhc897v019lfd4ck7ktlg0q0h